Antileishmanial activity of azithromycin against Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis, and Leishmania (Leishmania) chagasi.
Azithromycin, an azalide antibiotic, is highly concentrated within different phagocytic cells, especially macrophages. The potential antileishmanial activity of azithromycin against three species of Leishmania from the New World was assessed using in vitro models. Azithromycin decreased viability of promastigote cultures of Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis, and Leishmania (Leishmania) chagasi as determined by the colorimetric Alamar blue assay. In amastigote intracellular cultures, a significant decrease in infected macrophages counts was observed for all three species with IC(50) of 20.83 (27 micromol/L), 2.18 (2.7 micromol/L), and 6.12 (7.8 micromol/L) microg/mL, respectively. Azithromycin showed in vitro activity against L. (L.) amazonensis, L. (V.) braziliensis, and L. (L.) chagasi and may offer an alternative to current leishmaniasis treatment.
de Oliveira-Silva
Fernanda
F
Laboratory of Clinical Research, Instituto René Rachou, Fundação Oswaldo Cruz-Fiocruz, CEP 30.190-002 Belo Horizonte, Minas Gerais, Brazil.
de Morais-Teixeira
Eliane
E
Rabello
Ana
A
D000818:Animals; D000981:Antiprotozoal Agents / Q000494:pharmacology; D017963:Azithromycin / Q000494:pharmacology*; D007891:Leishmania / Q000187:drug effects* / Q000254:growth & development; D007892:Leishmania braziliensis / Q000187:drug effects* / Q000254:growth & development; D018314:Leishmania infantum / Q000187:drug effects* / Q000254:growth & development; D007894:Leishmania mexicana / Q000187:drug effects* / Q000254:growth & development; D008264:Macrophages / Q000187:drug effects / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D012044:Regression Analysis
D000981:Antiprotozoal Agents; D017963:Azithromycin